Investment analysts at Citigroup initiated coverage on shares of Gilead Sciences (NASDAQ:GILD - Get Free Report) in a note issued to investors on Thursday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $125.00 price target on the biopharmaceutical company's stock. Citigroup's target price suggests a potential upside of 34.95% from the stock's previous close.
A number of other analysts also recently issued reports on GILD. Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $75.00 to $81.00 and gave the company a "sector perform" rating in a report on Thursday, November 7th. BMO Capital Markets increased their price target on Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Robert W. Baird raised their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. Wells Fargo & Company increased their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Finally, Truist Financial boosted their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research note on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $93.10.
Check Out Our Latest Analysis on GILD
Shares of NASDAQ GILD opened at $92.63 on Thursday. The firm has a market cap of $115.32 billion, a P/E ratio of 1,029.22, a price-to-earnings-growth ratio of 2.91 and a beta of 0.17. The business's 50 day moving average is $85.95 and its 200-day moving average is $75.57. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.29 EPS. Equities research analysts predict that Gilead Sciences will post 4.39 earnings per share for the current year.
In other news, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in GILD. Koshinski Asset Management Inc. bought a new position in Gilead Sciences during the first quarter worth $217,000. Dorsey & Whitney Trust CO LLC grew its stake in shares of Gilead Sciences by 16.1% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 12,613 shares of the biopharmaceutical company's stock valued at $924,000 after buying an additional 1,746 shares during the period. GM Advisory Group LLC bought a new stake in Gilead Sciences in the 1st quarter valued at about $263,000. Banco Santander S.A. acquired a new position in Gilead Sciences during the 1st quarter worth approximately $15,827,000. Finally, M&G Plc bought a new position in Gilead Sciences in the first quarter worth approximately $7,082,000. 83.67% of the stock is currently owned by institutional investors.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.